{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:55:34Z","timestamp":1792569334230,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012030","name":"Yakult Honsha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10147-020-01803-w","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T10:03:16Z","timestamp":1603274596000},"page":"345-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of S-1 plus oxaliplatin 130\u00a0mg\/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: a phase II trial (KSCC1501A)"],"prefix":"10.1007","volume":"26","author":[{"given":"Tomomi","family":"Kashiwada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kawanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Fukahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Emi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Kyushu Study Group of Clinical Cancer (KSCC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"1803_CR1","first-page":"26","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Barsouk A (2019) Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 14:26\u201338","journal-title":"Prz Gastroenterol"},{"issue":"3","key":"1803_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221","journal-title":"Lancet Oncol"},{"key":"1803_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20:1\u201319","journal-title":"Gastric Cancer"},{"key":"1803_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdy498","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Van Cutsem E, Narita Y et al (2019) Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 30:34\u201343","journal-title":"Ann Oncol"},{"key":"1803_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s10120-011-0007-7","volume":"14","author":"F Montagnani","year":"2011","unstructured":"Montagnani F, Turrisi G, Marinozzi C et al (2011) Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 14:50\u201355","journal-title":"Gastric Cancer"},{"key":"1803_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36\u201346","journal-title":"N Engl J Med"},{"issue":"9","key":"1803_CR7","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J ClinOncol 26(9):1435\u20131442","journal-title":"J ClinOncol"},{"key":"1803_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 26:141\u2013148","journal-title":"Ann Oncol"},{"key":"1803_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01101-4","author":"K-W Lee","year":"2020","unstructured":"Lee K-W, Chung I-J, Ryu M-H et al (2020) Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer. https:\/\/doi.org\/10.1007\/s10120-020-01101-4","journal-title":"Gastric Cancer"},{"key":"1803_CR10","volume-title":"National Cancer Institute common terminology criteria for adverse events v 4.0","author":"National Cancer Institute","year":"2009","unstructured":"National Cancer Institute (2009) National Cancer Institute common terminology criteria for adverse events v 4.0. National Cancer Institute, Bethesda"},{"key":"1803_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101\u2013112","journal-title":"Gastric Cancer"},{"issue":"2","key":"1803_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"1803_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12885-017-3937-6","volume":"18","author":"H Saeki","year":"2018","unstructured":"Saeki H, Emi Y, Oki E et al (2018) Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced\/recurrent gastric cancer previously untreated with chemotherapy. BMC Cancer 18:57","journal-title":"BMC Cancer"},{"key":"1803_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","volume":"48","author":"GM Kim","year":"2012","unstructured":"Kim GM, Jeung HC, Rha SY et al (2012) A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 48:518\u2013526","journal-title":"Eur J Cancer"},{"key":"1803_CR15","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s10147-018-1308-1","volume":"23","author":"Y Kito","year":"2018","unstructured":"Kito Y, Machida N, Kawai S et al (2018) Phase II study of S-1 plus oxaliplatin 130 mg\/m2 in Japanese patients with advanced gastric cancer. Int J Clin Oncol 23:1084\u20131089","journal-title":"Int J Clin Oncol"},{"key":"1803_CR16","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235","journal-title":"Lancet Oncol"},{"key":"1803_CR17","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471","journal-title":"Lancet"},{"key":"1803_CR18","unstructured":"Teysuno (S-1) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/001242\/WC500104415.pdf. Accessed 5 Feb 2020"},{"key":"1803_CR19","unstructured":"ELOXATIN (oxaliplatin) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021759s012lbl.pdf. Accessed 5 Feb 2020"},{"key":"1803_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00595-019-01896-5","volume":"50","author":"M Tokunaga","year":"2020","unstructured":"Tokunaga M, Sato Y, Nakagawa M et al (2020) Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surg Today 50:30\u201337","journal-title":"Surg Today"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01803-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01803-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01803-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:03:51Z","timestamp":1634774631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01803-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1803"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01803-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"12 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TK has no financial conflicts of interest to disclose concerning this study. K.S. reports personal fees from SHIONOGI & CO., LTD., personal fees from Takeda Pharmaceutical Company Limited, personal fees from Taiho Pharmaceutical Co Ltd, personal fees from ONO PHARMACEUTICAL CO., LTD., personal fees from Merck Biopharma Co., Ltd, personal fees from NIPPON KAYAKU Co., Ltd., personal fees from Asahi Kasei Pharma, from Eisai Co., Ltd., personal fees from Bayer Yakuhin, Ltd., personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from CHUGAI PHARMACEUTICAL CO., LTD., personal fees from MOCHIDA PHARMACEUTICAL CO.,LTD., personal fees from Eli Lilly Japan K.K., personal fees from DAIICHI SANKYO COMPANY, LIMITED, outside the submitted work. AM received honoraria from Lilly, Chugai and Takeda. EO received lecture fee from Merck Biopharma Co., Ltd., Bayer Yakuhin Japan, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly, Yakult Honsha Co., Ltd., and Takeda Pharmaceutical Co., Ltd. E.B. received grants and personal fees from Ono, Merck-Serono, Taiho, Chugai and Daiichi-Sankyo and personal fees from BMS, Takeda, Eli lilly, Tsumura, Kyowa-Kirin and Yakult, outside the submitted work. Other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}